Enteris BioPharma names Khosla its new CEO

By Emily Bader
Boonton | May 4, 2020 at 11:19 am

Enteris Biopharma Inc., a Boonton-based biotechnology company, announced on Monday it has hired Rajiv Khosla as its new CEO, effective immediately. Khosla is replacing Joel Tune, the CEO since 2016.

“Rajiv brings a wealth of experience and expertise from a distinguished career as an industry executive and more recently as a consultant advising small biopharmaceutical companies, specifically regarding optimizing the monetization of intellectual property. His business development experience and proven track record, not to mention a deep knowledge of drug delivery systems, including oral delivery technologies, will be critical to Enteris as the company seeks to capture more value-creating opportunities and maximize the potential of its Peptelligence platform,” Winston Black, chairman and CEO of SWK Holdings, the holding company of Enteris, said.

Khosla, who has more than 30 years of experience in the biopharmaceutical industry, will be responsible for leading the company as it looks for growth opportunities built around Peptelligence, its proprietary oral peptide and small molecule drug delivery platform. He will also expand on the company’s internal and external programs as well as develop new licensing and partnership opportunities.

“I greatly look forward to working with the Enteris and SWK management teams to build on the momentum that began with the acquisition and continued support by SWK, which extended into 2020 with the expansion of our executive team,” Khosla said. “From its founding in 2013, Enteris has established itself as a leader in the oral peptide market, yet I believe the company has only begun to realize its vast potential. Peptelligence is a potential game changer for drug makers offering an opportunity to reshape therapeutic categories and treatment paradigms. I am humbled and excited to be afforded the opportunity to lead Enteris. I would like to thank Joel Tune for his vision and leadership, which was instrumental in enabling the company to achieve the successes it has to date.”

Prior to Enteris, Khosla founded CEUTEC LLC, a business development consultancy serving biopharmaceutical companies and venture capital firms. Before that, he held several senior roles at biopharma companies, including vice president of business development at the former Biovail Corp. and vice president and general manager, healthcare at Sensient Technology.

Emily Bader | ebader@roi-nj.com | @emilybader